HRP20180865T1 - Kristalni oblik abakavira koji uglavnom ne sadrži otapalo - Google Patents

Kristalni oblik abakavira koji uglavnom ne sadrži otapalo Download PDF

Info

Publication number
HRP20180865T1
HRP20180865T1 HRP20180865TT HRP20180865T HRP20180865T1 HR P20180865 T1 HRP20180865 T1 HR P20180865T1 HR P20180865T T HRP20180865T T HR P20180865TT HR P20180865 T HRP20180865 T HR P20180865T HR P20180865 T1 HRP20180865 T1 HR P20180865T1
Authority
HR
Croatia
Prior art keywords
abacavir
crystalline form
solvent
contain
essentially free
Prior art date
Application number
HRP20180865TT
Other languages
English (en)
Inventor
Martí BARTRA SANMARTÍ
Ramón Berenguer Maimó
Jordi Benet-Buchholz
Lluís SOLÀ I CARANDELL
Original Assignee
Esteve Química, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39528214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180865(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Química, S.A. filed Critical Esteve Química, S.A.
Publication of HRP20180865T1 publication Critical patent/HRP20180865T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Claims (4)

1. Kristalni oblik abakavira koji uglavnom ne sadrži otapalo i ne sadrži solvate formule (I), , naznačen time što ima difraktogram rendgenskih zraka na prahu s karakterističnim maksimumima na otprilike 8,0, 10,0, 10,2, 10,6, 11,9, 12,4, 12,7, 15,0, 16,1, 16,6, 19,5, 20,2, 20,6, 20,7, 21,9, 23,0, 23,9, te 25,0 °2θ uz upotrebu zračenja CuKα1 (λ = 1,54060 Å); i što ima čistoću veću od 99%.
2. Kristalni oblik abakavira u skladu s patentnim zahtjevom 1, naznačen time što dodatno ima difraktogram rendgenskih zraka na prahu kao na SL. 1.
3. Farmaceutski pripravak, naznačen time što sadrži kristalni oblik abakavira koji uglavnom ne sadrži otapalo i ne sadrži solvate u skladu s bilo kojim od patentnih zahtjeva 1-2, uz odgovarajuće količine farmaceutskih pomoćnih tvari ili podloga.
4. Kristalni oblik abakavira koji uglavnom ne sadrži otapalo i ne sadrži solvate u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što je namijenjen upotrebi u liječenju i/ili profiolaksi infekcija HIV-om.
HRP20180865TT 2008-01-21 2018-06-04 Kristalni oblik abakavira koji uglavnom ne sadrži otapalo HRP20180865T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08382004A EP2085397A1 (en) 2008-01-21 2008-01-21 Crystalline form of abacavir
US3844108P 2008-03-21 2008-03-21
EP14198021.9A EP2899193B1 (en) 2008-01-21 2009-01-21 Crystalline form of abacavir that is essentially free of solvent

Publications (1)

Publication Number Publication Date
HRP20180865T1 true HRP20180865T1 (hr) 2018-08-24

Family

ID=39528214

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180865TT HRP20180865T1 (hr) 2008-01-21 2018-06-04 Kristalni oblik abakavira koji uglavnom ne sadrži otapalo

Country Status (15)

Country Link
US (1) US9056864B2 (hr)
EP (3) EP2085397A1 (hr)
JP (1) JP5468553B2 (hr)
KR (1) KR20100103710A (hr)
CN (1) CN101925602B (hr)
AU (1) AU2009207735A1 (hr)
CA (1) CA2711059A1 (hr)
ES (2) ES2540461T3 (hr)
HR (1) HRP20180865T1 (hr)
HU (1) HUE037892T2 (hr)
IL (1) IL206731A (hr)
MX (1) MX2010007923A (hr)
RU (1) RU2010134904A (hr)
WO (1) WO2009092716A1 (hr)
ZA (1) ZA201004762B (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US20150290235A1 (en) * 2012-11-23 2015-10-15 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
CN105315280A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种阿巴卡韦结晶体及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672973A4 (hr) 1973-05-11 1976-05-14
US4355032B2 (en) 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5981500A (en) * 1994-01-12 1999-11-09 Pfizer Inc. Antiparasitic agents related to the milbemycins and avermectins
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
DE69709933T2 (de) * 1996-05-31 2002-08-29 C & C Res Lab Kyunggi Aromatische amidinderivate als selektive thrombininhibitoren
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
WO1999021861A1 (en) 1997-10-24 1999-05-06 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
US6548663B1 (en) * 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
MXPA03010028A (es) * 2001-05-22 2004-02-12 Pfizer Prod Inc Formas cristalinas de azitromicina.
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7211417B2 (en) * 2003-05-02 2007-05-01 Wyeth Holdings Corporation Antibiotic P175-A and semisynthetic derivatives thereof
US7067529B2 (en) * 2003-05-19 2006-06-27 Hoffmann-La Roche Inc. Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
EP1651612B9 (en) * 2003-07-22 2012-09-05 Astex Therapeutics Limited 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0320738D0 (en) * 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
WO2005049588A1 (en) 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for isolation of valsartan
JP2007515495A (ja) * 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
AU2005295350A1 (en) * 2004-10-20 2006-04-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
UA91716C2 (ru) * 2005-08-29 2010-08-25 САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА ПРОИЗВОДНОГО ПИРИДАЗИНО[4,5-b]ИНДОЛА
KR20070085703A (ko) * 2005-09-13 2007-08-27 시코르, 인크. 로큐로늄 브로마이드의 합성 방법
CN1763040A (zh) * 2005-09-15 2006-04-26 上海玛耀化学技术有限公司 阿巴卡韦的制造方法
EP1857458A1 (en) 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
EP1905772A1 (en) 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
CA2662586A1 (en) * 2006-09-28 2008-04-03 Esteve Quimica, S.A. Process for the preparation of abacavir
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP1939196A1 (en) 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists

Also Published As

Publication number Publication date
JP5468553B2 (ja) 2014-04-09
IL206731A0 (en) 2010-12-30
ES2540461T3 (es) 2015-07-09
CN101925602B (zh) 2014-03-12
IL206731A (en) 2014-06-30
ES2670802T3 (es) 2018-06-01
EP2085397A1 (en) 2009-08-05
EP2899193A1 (en) 2015-07-29
EP2242758B1 (en) 2015-03-18
US20100298354A1 (en) 2010-11-25
RU2010134904A (ru) 2012-02-27
HUE037892T2 (hu) 2018-09-28
JP2011510039A (ja) 2011-03-31
EP2899193B1 (en) 2018-03-14
WO2009092716A1 (en) 2009-07-30
EP2242758A1 (en) 2010-10-27
AU2009207735A1 (en) 2009-07-30
MX2010007923A (es) 2010-08-10
CN101925602A (zh) 2010-12-22
ZA201004762B (en) 2011-09-28
KR20100103710A (ko) 2010-09-27
US9056864B2 (en) 2015-06-16
CA2711059A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
IL258052A (en) Solid configurations of isoquinolinone derivatives, process for their preparation, compositions containing them and methods of use
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
JP2018024682A5 (hr)
HRP20180865T1 (hr) Kristalni oblik abakavira koji uglavnom ne sadrži otapalo
HRP20151299T1 (hr) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
JP2012500805A5 (hr)
HRP20160208T4 (hr) Polimorfi dasatiniba i postupak za njihovu pripremu
JP2015531773A5 (hr)
JP2010530897A5 (hr)
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
HRP20180444T1 (hr) 9-aminometil-supstituirani tetraciklinski spojevi
CO6410293A2 (es) Nueva formula cristalina vi de la agomelatina preparación y uso de la misma
JP2016510323A5 (hr)
JP2010516681A5 (hr)
JP2007532560A5 (hr)
HRP20160520T1 (hr) ČVRSTI OBLICI KOJI SADRŽE N-(5-TERC-BUTIL-IZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-IL-ETOKSI)IMIDAZO[2,1-b]BENZOTIAZOL-2-IL]FENIL}UREJU, NJIHOVI SASTAVI I NJIHOVE UPORABE
JP2014524442A5 (hr)
HRP20231588T3 (hr) Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja
JP2011527299A5 (hr)
JP2009521414A5 (hr)
JP2017514910A5 (hr)
JP2012531408A5 (hr)
JP2011510079A5 (hr)
MX2009001067A (es) Formas cristalinas de analogos de rapamicina.
JP2013507408A5 (hr)